PD-L1 CPS is a continuous IHC score used as an eligibility threshold for ICI-containing r...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PDL1-CPS-GASTRIC |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-05-07 | actionability review required |
| Diseases | DIS-GASTRIC |
| Sources | SRC-CHECKMATE-649-JANJIGIAN-2022 SRC-ESMO-GASTRIC-2024 SRC-NCCN-GASTRIC-2025 |
Actionability Facts
| Biomarker | BIO-PDL1-CPS |
|---|---|
| Disease | DIS-GASTRIC |
| ESCAT tier | IA |
| Recommended combinations | nivolumab + fluoropyrimidine + platinum (CPS≥5, 1L per SRC-NCCN-GASTRIC-2025, SRC-ESMO-GASTRIC-2024), nivolumab + FOLFOX/XELOX (CPS≥1 broader population per SRC-CHECKMATE-649-JANJIGIAN-2022) |
| Evidence summary | PD-L1 CPS is a continuous IHC score used as an eligibility threshold for ICI-containing regimens in metastatic gastric/GEJ adenocarcinoma. Thresholds vary by regimen: CPS ≥5 — nivolumab + fluoropyrimidine + platinum (CheckMate-649; mOS 14.4 vs 11.1 mo, HR 0.71 in CPS≥5 subgroup); CPS ≥1 — nivolumab + chemo as broader population (CM-649); CPS ≥1 — pembrolizumab + trastuzumab + chemo for HER2+ disease (KEYNOTE-811, covered separately in BMA-HER2-AMP-GASTRIC). Per NCCN and ESMO 2024, PD-L1 CPS testing by IHC 22C3 pharmDx is mandatory prior to 1L treatment selection. Threshold-gated indication selection is performed by the algorithm layer (IND-GASTRIC-METASTATIC-1L-PDL1-CHEMO-ICI); this BMA entry surfaces ESCAT tier context for tumor-board discussion only. |
Notes
Variant_qualifier is null (gene-level) — CPS is a continuous score; specific threshold gating (CPS≥5 vs ≥1) is enforced by the indication layer, not this BMA cell. This entry exists to prevent the render layer from showing "Not in KB" for a well-defined, FDA-approved biomarker. KEYNOTE-811 evidence is attributable to BMA-HER2-AMP-GASTRIC to avoid overlap.
Used By
No reverse references found in the YAML corpus.